株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ヒト微生物叢(ヒトマイクロバイオーム)の世界市場:成長、動向、予測(2019~2024年)

Human Microbiome Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 391460
出版日 ページ情報 英文 116 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
ヒト微生物叢(ヒトマイクロバイオーム)の世界市場:成長、動向、予測(2019~2024年) Human Microbiome Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年02月01日 ページ情報: 英文 116 Pages
概要

世界のヒト微生物叢(ヒトマイクロバイオーム)市場は、2024年にかけCAGR22.60%で拡大すると予測されています。市場の成長を牽引しているのが、生活習慣病の発症率上昇と高齢化です。

当レポートでは、世界のヒト微生物叢(ヒトマイクロバイオーム)市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場の定義動向

  • 市場概要
  • 市場促進因子
    • 生活習慣病の発症率上昇
    • 高齢化
  • 市場阻害因子
    • 包括的研究の不足
    • 厳しい政府の規制
  • 業界の魅力度:ポーターズファイブフォース分析

第5章 市場セグメンテーション

  • 用途別
    • 治療
    • 診断
  • 疾患別
    • 肥満
    • 糖尿病
    • 自己免疫疾患
    • 胃腸疾患
    • 中枢神経系疾患
    • その他
  • 製品別
    • プロバイオティクス
    • プレバイオティクス
    • シンボリティクス
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合環境

  • 企業プロファイル
    • Enterome Bioscience
    • Yakult
    • DuPont
    • Seres Therapeutics
    • Vithera Pharmaceuticals
    • Second Genome Inc.
    • Synthetic Biologics Inc.
    • Vedanta Biosciences Inc.
    • Osel Inc.
    • Synlogic Inc.

第7章 市場の機会と将来動向

目次
Product Code: 50089

Market Overview

The global human microbiome market is expected to show a CAGR of 22.60% during the forecast period. The key factors propelling the growth of this market are increasing incidence of lifestyle-related diseases and growing geriatric population.

The rising incidence of lifestyle-related diseases, globally, is a strong driver of the human microbiome market, as therapeutics may provide an alternative route to tackle significant healthcare challenges, such as obesity. The increasing occurrence of autoimmune disorders and antibiotic resistance are also important areas, which are in great need of fresh treatment approaches, and for which, microbiome therapies may have a significant impact over the next few years. With advancements in precision medicine, personalized nutrition is also playing a crucial role. Microbiome technologies strive for novel developments in the area. Cardiovascular diseases (CVD) continue to be the major cause of mortality, representing about 30% of all deaths, worldwide. Lifestyle-related diseases, like hypertension, diabetes mellitus, dyslipidaemia, and overweight/obesity, are the major risk factors for the development of CVD. With rapid economic development and increasing westernization of lifestyles in the past few decades, the prevalence of these diseases has reached alarming proportions in the recent years, which is expected to boost the growth of the human microbiome market.

Scope of the Report

The global human microbiome market comprises various therapeutic and diagnostic products that include human microbiota. The market also includes disease indication. The size of the market has been estimated based on the revenues generated from therapies and diagnostic techniques.

Key Market Trends

Therapeutic Applications is Expected to hold the Highest Market Share

The therapeutic applications segment is expected to have the largest market share during the forecast period and is likely to register a CAGR of 22.93%.

The microbiome-based products for therapeutics are still in the development phase. There are a number of organizations that are developing products across various disease areas in the human microbiome space. Companies have developed their own proprietary technology platforms and innovative approaches to microbiome-based treatment. The most common strategy deployed for a variety of products is the use of natural, live bacteria, either as a single agent or in a mixture form. Some companies are engineering bacteria and are programing them to take over certain physiologic functions to tackle rare disorders.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America currently dominates the market for human microbiome and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. It is also the largest market for microbiome-based products, globally. The growth of the market is majorly due to the high level of awareness about the beneficial aspects of microbiome-based products and initiatives, like the NIH human microbiome project, which have been responsible for generating a holistic understanding of concepts, like metagenomic and whole genome sequencing.

Competitive Landscape

The human microbiome market is less competitive currently and consists of several players that are coming up with products. Companies, like Yakult, DuPont, Series Therapeutics, Second Genome, and Synthetic Biologics, hold substantial shares in the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Lifestyle-related Diseases
    • 4.2.2 Growing Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 Lack of Comprehensive Research
    • 4.3.2 Stringent Government Regulations
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Application
    • 5.1.1 Therapeutics
    • 5.1.2 Diagnostics
  • 5.2 Disease
    • 5.2.1 Obesity
    • 5.2.2 Diabetes
    • 5.2.3 Autoimmune Disorder
    • 5.2.4 Cancer
    • 5.2.5 Gastrointestinal Disorders
    • 5.2.6 Central Nervous System Disorders
    • 5.2.7 Other Diseases
  • 5.3 Product
    • 5.3.1 Probiotics
    • 5.3.2 Prebiotics
    • 5.3.3 Symboitics
    • 5.3.4 Other Products
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Enterome Bioscience
    • 6.1.2 Yakult
    • 6.1.3 DuPont
    • 6.1.4 Seres Therapeutics
    • 6.1.5 Vithera Pharmaceuticals
    • 6.1.6 Second Genome Inc.
    • 6.1.7 Synthetic Biologics Inc.
    • 6.1.8 Vedanta Biosciences Inc.
    • 6.1.9 Osel Inc.
    • 6.1.10 Synlogic Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top